650results about How to "Retain biological activity" patented technology

Embodiments of the invention provide for compositions comprising purified polypeptides such as purified Concanavalin A (ConA) mutants. In addition, embodiments provide for polypeptides and nucleic acids encoding those polypeptides, such as mutant ConA with reduced dimer-dimer interactions compared to wild type ConA. Some embodiments also provide for sensors comprising the polypeptides disclosed herein. The embodiments also provide an improved method of producing recombinant mutant ConA.

The invention relates to the field of bio-materials, and especially relates to an acellular matrix repairing gel and a new method for preparing the same. The invention discloses the acellular matrix repairing gel and the method for preparing the same, wherein the method includes steps of acellular treatment and gelatinization treatment on tissue and organs from mammal animals to prepare the acellular matrix repairing gel. The acellular matrix repairing gel is eliminated in immunogenicity of heterologous and foreign tissue, so that activity of extracellular matrix components of the tissue is maintained as more as possible. The gel can specially repair damaged tissue and organs of human body, is strong in applicability, is suitable for requirements of various irregular-shaped repair zones and different position environments in body and has a huge clinical value.

Methods and compositions for making glycoproteins, both in vitro and in vivo, are provided. One method involves incorporating an unnatural amino acid having a N-acetylgalactosamine moiety into a protein; optionally, the N-acetylgalactosamine-containing unnatural amino acid can be further modified with additional sugars.

A method for the layer-by-layer assembly of a free standing thin film includes the steps of preparing a support with a suitable substrate; forming a thin film having a plurality of layers onto the substrate utilizing a layer-by-layer assembly process; removing the substrate and thin film from the support; and separating the substrate from the thin film. Various compounds improving the strength, flexibility, tension and other mechanical properties may be included in the assembly to improve the structural quality of the film. Similar effect may also be achieved by cross-linking the applied layers.

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

A method of producing a healthcare yang-invigorating preparation for males is provided. The method is characterized in that: male silkworm pupa-cordyceps militaris-oyster peptides prepared by subjecting raw materials including male silkworm pupae, cordyceps militaris (L.) Link and oyster to enzymolysis, a composite extract prepared from mulberry fruit, barbary wolfberry fruit, palmleaf raspberry fruit, solomonseal rhizome, common yam rhizome, gordon euryale seed, poria, jujube kernels, cortex cinnamomi, Chinese date and ginseng and broken pine pollen prepared from pine pollen are added and fully mixed, an excipient is added into the mixture and the mixture is prepared into granules, capsules, and a tablet candy preparation according to conventional preparing processes. Compatibility of components adopted is scientific. An adopted preparing process is unique and simple. According to the method and the preparation, a production process is simple, the preparation is simple to eat, has effects of tonifying the kidney and qi, tonifying the lung and kidney, promoting sperm production, boosting marrow, invigorating the spleen and the stomach, improving microcirculation of human bodies, eliminating moisture, removing paralysis, boosting immunity, preventing fatigue, resisting viruses, strengthening bodies, invigorating yang and treating impotence, has obvious curative effects, mild functions and no side or toxic effects, and is an ideal healthcare yang-invigorating preparation for males.

The invention discloses an antigen-free collagen aggregate and a preparation method thereof. The preparation method is characterized by comprising the following steps: with traceable animal skin or tendo calcaneus as a raw material, performing operations by the process such as fleshing, stripping fascia, degreasing, removing foreign protein and decellularizing; performing fine purification on the animal skin or tendo calcaneus, and then carrying out separation and purification on the collagen aggregate by the methods of acid fluffing, homogenizing, salting out for a plurality of times, centrifuging for a plurality of times and the like, thereby finally obtaining the antigen-free collagen aggregate. The collagen aggregate is a mixture of a collagen fiber and a collagen bundle, and has a periodic light and shade horizontal grain structure; and the space between the horizontal grains is about 67nm. The material has good biocompatibility, biodegradability, mechanical property and hemostatic performance, also has the characteristics of low antigenicity, biological activity and the like, and can be widely applied to preparation of biomedical materials such as a hemostatic material, a tissue engineering material, a biological dressing, a biodegradable medical suture and a plastic material.

VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the coumarin unnatural amino acid L-(7-hydroxycoumarin-4-yl) ethylglycine into proteins produced in eubacterial host cells such as E. coli. The invention provides, for example but not limited to, novel orthogonal synthetases, methods for identifying and making the novel synthetases, methods for producing proteins containing the unnatural amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine and related translation systems.

The present invention provides a method for preparing hollow polymer nanofibers by using a coaxial electrospinning technology. The method comprises the following steps: 1) adopting glycerol or a mixture of glycerol and water as an inner phase electrospinning liquid of coaxial electrospinning; 2) adopting a polymer solution as an outer phase electrospinning liquid; 3) respectively connecting the inner phase electrospinning liquid and the outer phase electrospinning liquid to a liquid inlet of a coaxial electrospinning nozzle; 4) controlling flow rates of the inner phase electrospinning liquid and the outer phase electrospinning liquid, and carrying out coaxial electrospinning to obtain the hollow polymer nanofibers on a receiving plate. Compared with the existing preparation technology, the preparation method of the present invention has the following advantages that: the liquid glycerol is adopted as the inner phase electrospinning liquid so as to prepare the hollow nanofibers through a one-step method, such that the preparation process is simple; the glycerol provides good biocompatibility for most of bioactive macromolecules, and bioactive substances such as biological enzymes and the like are added to the inner phase electrospinning liquid, such that efficient in-situ loading of the bioactive substances in the hollow nanofiber cavity can be achieved.

The invention belongs to the field of biological engineering and relates to chitosan modification. The chitosan modification comprises the following steps of: adding protein or polypeptide; adding transglutaminase; adjusting the pH value; removing precipitates after full reaction; and desalting and drying for modification. The modified chitosan produced by the technical scheme disclosed by the invention is good in water solubility, does not generate precipitate at the pH value of 3-10, and is small in viscosity. Moreover, the functions including strong adsorption, antibacterial property and the like of the chitosan are kept, and the application prospect is extensive.

Microencapsulated polyphenol compositions suitable for use in food and beverage products are provided. Microencapsulation significantly reduces the astringency and / or bitterness of the polyphenol compositions and protects the polyphenol compositions from oxidation, ingredient interactions, enzymatic degradation, and the like while maintaining gastrointestinal bioavailability within the digestive system.

The invention discloses a method for preparing active peptide of laver. The method is characterized by comprising the following steps of: drying and crushing porphyra yezoensis serving as a raw material, taking the part with particle size of between 150 and 200 meshes, adding water into the raw material according to a weight volume ratio of the raw material to water as 1 to 100g / mL and uniformly mixing; filling the material liquid into an ultrasonic cell disruptor for disruption and centrifuging to obtain supernatant; adjusting the pH value of the supernatant to be 7.0, adding papain for enzymolysis, inactivating, cooling and centrifuging to obtain enzymatic hydrolyzate; and performing ultrafiltration on the enzymatic hydrolyzate, concentrating filtrate and performing vacuum freeze dryingto obtain a freeze-dried product of the active peptide of the laver. The method has the advantages of more reasonable preparation process, simple process, high operability and high extraction rate; the prepared active peptide of the laver contains fewer impurities; and the biological activity is also kept to the greatest extent.

The invention provides a method for preparing a ginseng and coix seed mixture and a ginseng and coix seed paste. Raw materials comprise 1 to 10 parts of ginseng, 10 to 30 parts of coix seed, 2 to 10 parts of lotus seed, 10 to 35 parts of glutinous rice, 5 to 20 parts of black rice, 10 to 30 parts of flour, 2 to 15 parts of black sesame, 1 to 6 parts of walnut kernel, 1 to 10 parts of peanut kernel, 3 to 10 parts of malto dextrin, 1 to 4 parts of black soya bean, 1 to 4 parts of small red bean, 1 to 10 parts of edible modified starch and 2 to 10 parts of white granulated sugar. The ginseng is subjected to supercritical CO2 extraction, the green production process is really realized, and the total extraction rate of active substances such as ginsenoside and the like is over 90 percent. The obtained product is fine powder without cakes, is easy to store and convenient to use, has characteristics of fine and smooth texture, delicious taste and tasty mouthfeel, cleanness and faint scent, and high digestion and absorption rate of natural nutrients, and maintains natural nutrient components of the raw materials, and improves the mouthfeel and the nutrient component absorption rate.

The present invention provides long-acting sustained-release formulations of drugs such as proteins or peptides, which are injectable, completely biodegradable and safe, as well as ensuring efficient encapsulation of the drugs such as proteins or peptides without inhibiting their biological activity. It is possible to achieve injectable sustained-release formulations that ensure efficient encapsulation and long-term sustained release of drugs such as proteins or peptides while retaining their biological activity, when a solution containing a drug and a polysaccharide derivative such as hyaluronic acid having a crosslinkable functional group(s) or a salt thereof is dehydrated in microparticulate form starting from a dilute state, where crosslinking proceeds slowly, to reach a concentration which facilitates crosslinking, to thereby cause crosslinking reaction during concentration, so that the drug is encapsulated into the crosslinked polysaccharide to give drug-carrying microparticles.

The invention discloses a protein-coated fluorescent gold nanocluster as well as a preparation method and application thereof. The fluorescent gold nanocluster is an aprotinin-coated gold nanocluster,which is composed of aprotinin molecular and Au22 or Au21 or Au16. Compared with the prior art, the fluorescent gold nanocluster has fluorescence, the activity of the aprotinin is not influenced, sothat the fluorescent gold nanocluster can be applied to fields of metal ion detection, biological imaging and protease detection.

The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

The invention belongs to the field of deep processing of foods and particularly relates to a production method for maca foods. The maca foods are prepared by the steps of pre-treating maca, grinding, carrying out enzymolysis, separating, digesting, homogenizing, drying and the like. The production method has the beneficial effects that a complex enzyme preparation composed of amylase, cellulose, hemicellulase and protease is used for extracting maca so that effective components in the maca can be effectively extracted; the dissolving speed of the maca is increased and the maca is very easy to absorb by a human body; the beneficial effects of the maca can be expressed very well and the aims of enhancing the immunity of a human body, adjusting the internal secretion, delaying aging and the like are realized. In an enzymolysis process, less water is added into the complex enzyme preparation to fuse the complex enzyme preparation so that the recycling rate of the maca is improved, the resource utilization rate is high and the extraction time is greatly shortened. With the adoption of a homogenization method, the enzymolyzed effective components can be uniformly and mutually mixed, so that the effective components can be rapidly dissolved in the water and are easily absorbed by the human body.

This invention is preparation procedure of the yolk antibody of high biological activity, belonging to the field of bioproduct and industrialized isolation technique. In this invention, we adopt the natural macromolecule gel high -extractive technique and hyperfiltration to extract the yolk-antibody of high biological activity from yolk at an industrialized level, annual output is upto 10 ton. the yolk-antibody content is about 30%-50%, meanwhile we could obtain some by-products like albumen powder, yolk powder, egg oil, vitellin and so on. In the invention high technology like bioimmunology and membrane separation is adopted. The invention is high-tech, high-usage, highly-automated and typical of green food and environmental-friendly.

The invention belongs to the technical field of comprehensive utilization of grape seeds, and concretely relates to a high-efficiency extraction and separation method of grape seed proanthocyanidin oligomer. The high-efficiency extraction and separation method of grape seed proanthocyanidin oligomer comprises the following steps: 1, low-temperature drying and crushing; 2, degreasing; 3, enzyme treatment; 4, proanthocyanidin extraction; 5, low-temperature concentration; 6, proanthocyanidin high polymer degradation; 7, purification; and 8, low-temperature concentration and drying. The extraction and separation method obviously improves the yield of grape seed proanthocyanidins and the content of proanthocyanidin oligomer in an extract liquid, the bioactivity of the proanthocyanidins is well reserved through low-temperature extraction and separation, and the highly pure proanthocyanidin oligomer is obtained through column chromatography grading purification.

The invention relates to tripterygium wilfordii diterpenes lactone derivates represented by the formula (1), optical isomers thereof and pharmaceutically acceptable salts and hydrate thereof, wherein C5 and C6 are combined by C-C or C=C bind; P and Q represent hydrogen, oxygen, hydroxyl, halogen, sulfhydryl, C1-C6 alkoxyl, C1-C6 alkylamino radical, or C1-C6 alksulfhydryl combined on positions C5 or C6 respectively when C5 and C6 are combined by C-C bind; and C14XY is combined at the position C14 with the structure shown in the view, and W and Z represent oxygen, hydroxyl, halogen, sulfhydryl, C1-C6 alkoxyl, C1-C6 alkylamino radical, or C1-C6 alksulfhydryl combined on positions C12 or C13 respectively, '-'combined with X, Y, Z, W, P and Q represent '' '' or '' ''. The invention further relates to a synthetic method thereof and the applications on preparing the medicine for treating hypertrophic tumor.

The invention relates to the technical field of medicines for treating diabetes, in particular to a fusion protein for treating diabetes and a preparation method for the fusion protein. The fusion protein is recombined by 2 to 8 Exendin-4-Linkers and a human IgGFc mutant; Linker is a flexible peptide fragment; and the human IgGFc mutant is an IgG1Fc, IgG2Fc or IgG4Fc mutant. The invention also discloses the preparation method for the fusion protein. The recombined fusion protein obtained by the steps of performing high-level expression in Chinese hamster ovary (CHO) cells, affiliating, and performing ion exchange and molecular sieve chromatography has the bioactivities of stimulating the secretion of insulin and inhibiting glucagon generated after dinner from being released which are possessed by Exendin-4, also has the characteristics of prolonging the half-life period of the Exendin-4 in serum, is used for treating type I and type II diabetes, can effectively reduce the psychological and physiological burden of patients, is safe in use and high in practicability, and can be massively produced and sold.

Synthetic and / or recombinant biologically active peptide derivatives of PTH(1-28), comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula: (a)X01ValSerGluIleGlnLeuMetHisAsn(SEQ ID NO:1);LeuGlyLysHisLeuAsnSerMetX02ArgValGluTrpLeuArgLysLysLeu(b) fragments thereof containing amino acids 1-24, 1-25, 1-26, or 1-27; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein: X01 is Ser, Ala or Gly; and X02 is Glu or Arg, provided that said peptide is not hPTH(1-26)NH2, hPTH(1-27)NH2 or hPTH(1-28)NH2.